Hanmi Pharm Shares Surge 30% on Genentech Obesity Drug Deal

Key Facts

Amid the intensifying global race to develop weight-loss treatments, Hanmi Pharm has seen a significant surge in its market valuation. According to reports, the company's shares jumped 30%, hitting the daily limit, following the announcement of a deal with Genentech, a subsidiary of Roche, regarding an obesity drug candidate. This surge reflects deep investor optimism regarding the commercial potential of partnering with a major global biotech firm in this high-growth sector.

This partnership arrives at a time of heightened interest in weight-management innovations within the biopharmaceutical industry, positioning Hanmi Pharm as a key player. Based on analyst data, the deal focuses on a promising therapeutic candidate, which triggered the exceptional stock gains immediately after the disclosure. This alliance is viewed as a significant positive catalyst that strengthens the standing of South Korean firms in the expanding global pharmaceutical market.

Regarding market action, the stock recorded strong gains at the close of August 24, 2026, driven by the momentum of this deal. On the macroeconomic front, traders are awaiting the release of UK inflation data on August 19, 2026, which may influence global market risk appetite, while focus remains on clinical trial developments stemming from this strategic collaboration.